British Poliomyelitis Vaccine

Poliomyelitis Vaccine

The Epidemiology of poliomgelitis has been investigated in our country Pasteur Institute; the incidence of Poliomgelitis, after the age of 4 years i's rare, in Iran.  Passive antibody of maternal origin do not interfere with production of active antibody after immunization.  Inactivated Polio Vaccine (salk) has been effective in reducing the incidence of poliomge­litis by approximately 90 per ...

Vaccine-associated paralytic poliomyelitis.

In the wake of the World Health Organization’s (WHO) program to eradicate poliomyelitis globally by the end of the year 2000 (in 1997 only 5,186 cases were reported world-wide), attention has focussed on the importance of good surveillance of acute flaccid paralysis, which is essential for a country to qualify for being declared polio-free, and on the occurrence of vaccine–associated paralytic ...

Stability Study of Razi Trivalent and Monovalent Oral Poliomyelitis Vaccine

Stability studies play a critical role in assuring product quality at all points in the vaccine life cycle. These studies used to determine vaccine expiry date and vaccine efficacy. Accelerated stability and long term stability study performed for three batches of trivalent oral poliomyelitis vaccine (OPV) and three batches of monovalent OPV (type1) manufactured by Razi institute. After samplin...

The 1954 Salk poliomyelitis vaccine field trial.

Stochastic Modeling of Vaccine-Derived Poliomyelitis

Since the introduction of vaccines against polio in the mid 1950s (Inactivated polio vaccine (IPV)) and the earl 1960s (Oral polio vaccine (OPV)), the control of polio has been successful. However, vaccine associated paralytic disease, which is caused by reversion of OPV, remains an unsolved issue in the present. Even though OPV has ability to induce a high level of intestinal immunity, it may ...